Newer drugs for epilepsy in children.
Newer drugs for epilepsy in children.
27 October 2008
National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]
Summary,
GUIDELINE OBJECTIVE(S)
To assess the effectiveness and cost-effectiveness of newer drugs for children with epilepsy
TARGET POPULATION
Children with epilepsy
INTERVENTIONS AND PRACTICES CONSIDERED
1. Antiepileptic drug therapy as monotherapy or combination therapy:
* Gabapentin
* Lamotrigine
* Oxcarbazepine
* Tiagabine
* Topiramate
* Vigabatrin (as an adjunctive therapy for partial seizures)
2. Assessment of risks and benefits of drugs in girls of child-bearing potential
3. Referral to specialists in persons with first seizure
4. Review of and monitoring of treatment
MAJOR OUTCOMES CONSIDERED
* Clinical effectiveness (e.g., seizure frequency, seizure-free intervals)
* Adverse effects
* Cost-effectiveness
National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]
Summary,
GUIDELINE OBJECTIVE(S)To assess the effectiveness and cost-effectiveness of newer drugs for children with epilepsy
TARGET POPULATION
Children with epilepsy
INTERVENTIONS AND PRACTICES CONSIDERED
1. Antiepileptic drug therapy as monotherapy or combination therapy:
* Gabapentin
* Lamotrigine
* Oxcarbazepine
* Tiagabine
* Topiramate
* Vigabatrin (as an adjunctive therapy for partial seizures)
2. Assessment of risks and benefits of drugs in girls of child-bearing potential
3. Referral to specialists in persons with first seizure
4. Review of and monitoring of treatment
MAJOR OUTCOMES CONSIDERED
* Clinical effectiveness (e.g., seizure frequency, seizure-free intervals)
* Adverse effects
* Cost-effectiveness
